All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
4th International Conference on Multiple Myeloma, European School of Haematology, 5–7 October, Mandelieu, France
At ESH 2018, Professor Maria-Victoria Mateos spoke to the MM Hub about clinical trial results in smoldering multiple myeloma (SMM). Professor Mateos explained most of these trials are focused on the high-risk subgroup who are symptomatic, who have a risk of progression of 50% at 2-years. The first trial in this setting was almost 9 years ago (as of 2018). It was a phase III trial investigating lenalidomide and dexamethasone versus no treatment in 120 patients with high-risk SMM. Treatment with len+dex was effective in delaying progression and also gave an OS benefit with low toxicity. When this video was recorded, there were 55 trials ongoing in this population, some with an objective to delay progression and others with an aim of curing.
Recent results of clinical trials in SMM
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox